Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

192927-63-2

Moxifloxacin HCl Monohydrate

192927-63-2
113507-06-5

Moxidectin

113507-06-5
509-80-8

mitraphylline

509-80-8
84878-61-5

Maduramicin Ammonium salt

84878-61-5
108-78-1

Melamine Monomer

108-78-1
298-59-9

Methylphenidate HCl

298-59-9
89226-75-5

Manidipine 2HCl

89226-75-5
151767-02-1

Montelukast Sodium Hydrate

151767-02-1
577953-88-9

Montelukast racemate

577953-88-9
672-99-1

4-Bromo-3,5-dimethylphenyl N-methylcarbamate

672-99-1
08/07/5188

Methyl mercaptan Na salt 15% in water

08/07/5188
577953-88-9

Montelukast dicyclohexylamine

577953-88-9
4441-15-0

Morpholin-2-one

4441-15-0
41100-52-1

Memantine HCl

41100-52-1
31431-39-7

Mebendazole

31431-39-7
52329-60-9

Mebendazole amine

52329-60-9
120739-62-0

N-[(6-chloropyridin-3-yl)methyl]-N-methylamine

120739-62-0
100-97-0

Methenamine

100-97-0
5939-37-7

7-Hydroxy Methotrexate

5939-37-7
532-03-6

Methocarbamol

532-03-6